157 related articles for article (PubMed ID: 34455749)
1. [The expression and prognostic value of PD-1, TIM-3, LAG-3 and BTLA in extranodal NK/T cell lymphoma].
Nie L; Liu XY; Ma RJ; Yuan XL; Jiang L; Yang J; Hu AX; Li Z; Zhu ZM
Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):598-602. PubMed ID: 34455749
[No Abstract] [Full Text] [Related]
2. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.
Datar I; Sanmamed MF; Wang J; Henick BS; Choi J; Badri T; Dong W; Mani N; Toki M; Mejías LD; Lozano MD; Perez-Gracia JL; Velcheti V; Hellmann MD; Gainor JF; McEachern K; Jenkins D; Syrigos K; Politi K; Gettinger S; Rimm DL; Herbst RS; Melero I; Chen L; Schalper KA
Clin Cancer Res; 2019 Aug; 25(15):4663-4673. PubMed ID: 31053602
[TBL] [Abstract][Full Text] [Related]
3. Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/T-CL.
Liao Z; Lv X; Liu S; He Z; Chen S; Wang L; Li W; Li Y
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e252-e258. PubMed ID: 29368793
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Co-inhibitory Receptor Expression in COVID-19 Infection Compared to Acute
Herrmann M; Schulte S; Wildner NH; Wittner M; Brehm TT; Ramharter M; Woost R; Lohse AW; Jacobs T; Schulze Zur Wiesch J
Front Immunol; 2020; 11():1870. PubMed ID: 32983106
[TBL] [Abstract][Full Text] [Related]
5. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
[TBL] [Abstract][Full Text] [Related]
6. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.
Anderson AC; Joller N; Kuchroo VK
Immunity; 2016 May; 44(5):989-1004. PubMed ID: 27192565
[TBL] [Abstract][Full Text] [Related]
7. Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer.
Al-Badran SS; Grant L; Campo MV; Inthagard J; Pennel K; Quinn J; Konanahalli P; Hayman L; Horgan PG; McMillan DC; Roxburgh CS; Roseweir A; Park JH; Edwards J
J Pathol Clin Res; 2021 Mar; 7(2):121-134. PubMed ID: 33338327
[TBL] [Abstract][Full Text] [Related]
8. [Expression of PD-1, TIM-3, LAG-3 and BTLA in diffuse large B-cell lymphoma and its effect on prognosis].
Liu XY; Yuan XL; Ma RJ; Xu H; Yang SW; Nie L; Zhang L; Hu AX; Li Z; Zhu ZM
Zhonghua Yi Xue Za Zhi; 2020 Sep; 100(36):2846-2853. PubMed ID: 32988145
[No Abstract] [Full Text] [Related]
9. Expression of TIM-3 and LAG-3 in extranodal NK/T cell lymphoma, nasal type.
Feng Y; Zhong M; Liu Y; Wang L; Tang Y
Histol Histopathol; 2018 Mar; 33(3):307-315. PubMed ID: 28901003
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival.
Tu L; Guan R; Yang H; Zhou Y; Hong W; Ma L; Zhao G; Yu M
Int J Cancer; 2020 Jul; 147(2):423-439. PubMed ID: 31721169
[TBL] [Abstract][Full Text] [Related]
12. Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes.
Kamal AM; Wasfey EF; Elghamry WR; Sabry OM; Elghobary HA; Radwan SM
Clin Biochem; 2021 Oct; 96():13-18. PubMed ID: 34217699
[TBL] [Abstract][Full Text] [Related]
13. Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade.
Grabmeier-Pfistershammer K; Stecher C; Zettl M; Rosskopf S; Rieger A; Zlabinger GJ; Steinberger P
Clin Immunol; 2017 Oct; 183():167-173. PubMed ID: 28882621
[TBL] [Abstract][Full Text] [Related]
14. Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors.
Thommen DS; Schreiner J; Müller P; Herzig P; Roller A; Belousov A; Umana P; Pisa P; Klein C; Bacac M; Fischer OS; Moersig W; Savic Prince S; Levitsky V; Karanikas V; Lardinois D; Zippelius A
Cancer Immunol Res; 2015 Dec; 3(12):1344-55. PubMed ID: 26253731
[TBL] [Abstract][Full Text] [Related]
15. Expression of the checkpoint receptors LAG-3, TIM-3 and VISTA in peripheral T cell lymphomas.
Murga-Zamalloa CA; Brown NA; Wilcox RA
J Clin Pathol; 2020 Apr; 73(4):197-203. PubMed ID: 31672704
[TBL] [Abstract][Full Text] [Related]
16. Functional exhaustion of CD4
Ozkazanc D; Yoyen-Ermis D; Tavukcuoglu E; Buyukasik Y; Esendagli G
Immunology; 2016 Dec; 149(4):460-471. PubMed ID: 27565576
[TBL] [Abstract][Full Text] [Related]
17. Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.
Muhamad H; Suksawai N; Assanasen T; Polprasert C; Bunworasate U; Wudhikarn K
Acta Haematol; 2020; 143(1):78-88. PubMed ID: 31330525
[TBL] [Abstract][Full Text] [Related]
18. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
[TBL] [Abstract][Full Text] [Related]
19. Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis.
Lavon I; Heli C; Brill L; Charbit H; Vaknin-Dembinsky A
Front Immunol; 2019; 10():835. PubMed ID: 31134049
[No Abstract] [Full Text] [Related]
20. PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma.
Zelba H; Bedke J; Hennenlotter J; Mostböck S; Zettl M; Zichner T; Chandran A; Stenzl A; Rammensee HG; Gouttefangeas C
Cancer Immunol Res; 2019 Nov; 7(11):1891-1899. PubMed ID: 31484656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
